Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Circulating tumor cells in breast cancer.
Bidard FC, Proudhon C, Pierga JY. Bidard FC, et al. Among authors: proudhon c. Mol Oncol. 2016 Mar;10(3):418-30. doi: 10.1016/j.molonc.2016.01.001. Epub 2016 Jan 12. Mol Oncol. 2016. PMID: 26809472 Free PMC article. Review.
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).
Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A, L'Haridon T, Cottu P, Abadie-Lacourtoisie S, You B, Mousseau M, Dauba J, Del Piano F, Desmoulins I, Coussy F, Madranges N, Grenier J, Bidard FC, Proudhon C, MacGrogan G, Orsini C, Pulido M, Gonçalves A. Bonnefoi H, et al. Among authors: proudhon c. Ann Oncol. 2016 May;27(5):812-8. doi: 10.1093/annonc/mdw067. Epub 2016 Feb 18. Ann Oncol. 2016. PMID: 27052658 Free article. Clinical Trial.
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
Pierga JY, Bidard FC, Autret A, Petit T, Andre F, Dalenc F, Levy C, Ferrero JM, Romieu G, Bonneterre J, Lerebours F, Bachelot T, Kerbrat P, Campone M, Eymard JC, Mouret-Reynier MA, Gligorov J, Hardy-Bessard AC, Lortholary A, Soulie P, Boher JM, Proudhon C, Charafe-Jaufret E, Lemonnier J, Bertucci F, Viens P. Pierga JY, et al. Among authors: proudhon c. Ann Oncol. 2017 Jan 1;28(1):103-109. doi: 10.1093/annonc/mdw535. Ann Oncol. 2017. PMID: 28177480 Free article. Clinical Trial.
Circulating tumor cells: clinical validity and utility.
Cabel L, Proudhon C, Gortais H, Loirat D, Coussy F, Pierga JY, Bidard FC. Cabel L, et al. Among authors: proudhon c. Int J Clin Oncol. 2017 Jun;22(3):421-430. doi: 10.1007/s10147-017-1105-2. Epub 2017 Feb 25. Int J Clin Oncol. 2017. PMID: 28238187 Review.
Quantifying HER-2 expression on circulating tumor cells by ACCEPT.
Zeune L, van Dalum G, Decraene C, Proudhon C, Fehm T, Neubauer H, Rack B, Alunni-Fabbroni M, Terstappen LWMM, van Gils SA, Brune C. Zeune L, et al. Among authors: proudhon c. PLoS One. 2017 Oct 30;12(10):e0186562. doi: 10.1371/journal.pone.0186562. eCollection 2017. PLoS One. 2017. PMID: 29084234 Free PMC article.
44 results